Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 261-267

  Woods, Beth ^a   Paracha, Noman ^a   Scott, David A ^a   Thatcher, Nicholas ^b  

^a ICON PLC   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Cost effectiveness; Indirect comparison; Mesothelioma

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; RALTITREXED;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; FATIGUE; HEALTH CARE COST; HUMAN; INFECTION; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHLEBITIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COST-BENEFIT ANALYSIS; GLUTAMATES; GUANINE; HEALTH CARE COSTS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES;

EID: 84855417518     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.07.011     Document Type: Article

References (33)

1. Health and Safety Executive. Mesothelioma. Available from: [assessed 01.04.11]. http://www.hse.gov.uk/statistics/causdis/mesothelioma/.
2. Tan E., Warren N. Projection of mesothelioma mortality in Great Britain 2009, Health and Safety Executive.
3. Stahel R.A., Weder W., Lievens Y. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 5:126-128.
4. National Institute for Health and Clinical Excellence Final appraisal determination - pemetrexed for the treatment of malignant pleural mesothelioma 2007.
5. National Institute for Health and Clinical Excellence Health technology appraisal. Final scope - pemetrexed disodium for the treatment of malignant pleural mesothelioma 2005.
6. Muers M.F., Stephens R.J., Fisher P. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371(9625):1685-1694.
7. National Institute for Health and Clinical Excellence Final appraisal determination - pemetrexed disodium for the treatment of malignant pleural mesothelioma 2006.
8. Ellis P., Davies A.M., Evans W.K. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006, 1(6):591-601.
9. van Meerbeeck J.P., Gaafar R., Manegold C. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889.
10. Vogelzang N.J., Rusthoven J.J., Symanowski J. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
11. Bucher H.C., Guyatt G.H., Griffith L.E. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50(6):683-691.
12. Cordony A., Le R.C., Smala A. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value Health 2008, 11(1):4-12.
13. NICETAR 04/17. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Liverpool Reviews and Implementation Group; 2005.
14. Tappenden P., Jones R., Paisley S. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007, 11(12).
15. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal 2008.
16. Evidence Review Group (ERG) Pemetrexed in the treatment of non-small-cell-lung-cancer 2006, Liverpool Reviews and Implementation Group.
17. Collet D. Modelling survival data in medical research 2003, Chapman and Hall/CRC. 2nd ed.
18. Berghmans T., Paesmans M., Lalami Y. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38(2):111-121.
19. Summary of product characteristic. Pemetrexed (Alimta). Available from: [assessed 01.04.11]. http://www.medicines.org.uk/EMC/medicine/15513/SPC/Alimta+100mg+500mg+powder+for+concentrate+for+solution+for+infusion/.
20. Pimental F., Szczepura A., Thomas M. Quality-of-life (QoL) measures in advanced non-small cell lung cancer (NSCLC) patients and their association with treatment choices across 5 European countries: preliminary data from the ACTION study. J Clin Oncol 2005, 23(8081).
21. Single Technology Appraisal (STA). Submission to the National Institute for Health and Clinical Excellence. Pemetrexed in the treatment of non-small-cell-lung-cancer. Eli Lilly and Company; 2006.
22. Single Technology Appraisal (STA). Submission to the National Institute for Health and Clinical Excellence. Pemetrexed for the first-line treatment of non-small cell lung cancer. Eli Lilly and Company; 2008.
23. Bottomley A., Gaafar R., Manegold C. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 2006, 24(9):1435-1442.
24. Hazarika M., White R.M., Booth B.P. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005, 11(3):982-992.
25. British Medical Association and Royal Pharmaceutical Society of Great Britain British National Formulary (BNF-59) 2010.
26. Department of Health. NHS reference cost 2009. Appendix NSRC4. Available from: [assessed 01.04.11]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591.
27. Single Technology Appraisal (STA). Submission to the National Institute for Health and Clinical Excellence. Erlotinib: achieving clinical excellence in the treatment of relapsed non-small-cell-lung-cancer. Roche; 2006.
28. Single Technology Appraisal (STA). Submission to the National Institute for Health and Clinical Excellence. Pemetrexed in the maintenance treatment of advanced non-small-cell-lung-cancer. Eli Lilly and Company; 2009.
29. Addendum NICETAR 04/17. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Liverpool Reviews and Implementation Group; 2005.
30. Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2006, Oxford University Press Inc., NY, USA.
31. Drummond M.F., Sculpher M.J., Torrance G.W. Methods for the economic evaluation of health care programmes 2005, Oxford University Press Inc., NY, USA. 3rd ed.
32. Chapman A., Mulrennan S., Ladd B. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63(5):435-439.
33. Curtis L., Netten A. Unit cost of health and social care. Personal Social Services Research Unit (PSSRU) 2009, University of Kent, Kent, UK.